Abstract
Adrenergic and angiotensin receptors are prominent targets in pharmacological alleviation of cardiac remodeling and heart failure, but their use is associated with cardiodepressant side effects. Recent advances in our understanding of seven transmembrane receptor signaling show that it is possible to design ligands with "functional selectivity," acting as agonists on certain signaling pathways while antagonizing others. This represents a major pharmaceutical opportunity to separate desired from adverse effects governed by the same receptor. Accordingly, functionally selective ligands are currently pursued as next-generation drugs for superior treatment of heart failure.
| Original language | English |
|---|---|
| Journal | Trends in Cardiovascular Medicine |
| Volume | 20 |
| Issue number | 7 |
| Pages (from-to) | 221-7 |
| Number of pages | 7 |
| ISSN | 1050-1738 |
| DOIs | |
| Publication status | Published - Oct 2010 |
Keywords
- Adrenergic beta-Agonists
- Adrenergic beta-Antagonists
- Angiotensin II Type 1 Receptor Blockers
- Animals
- Heart Failure
- Humans
- Ligands
- Mice
- Mice, Transgenic
- Receptor, Angiotensin, Type 1
- Receptors, Adrenergic, beta
- Signal Transduction